{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:14:06Z","timestamp":1792502046963,"version":"4.5.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Primary debulking surgery (PDS), interval debulking surgery (IDS), and platinum-based chemotherapy are the current standard treatments for advanced ovarian cancer (OC). The time to initiation of adjuvant chemotherapy (TTC) could influence patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter retrospective cohort study of advanced (International Federation of Gynecology and Obstetrics (FIGO) stage III or IV) OC treated between 2014 and 2018 to assess progression-free survival (PFS) and overall survival (OS) in relation to TTC. All patients underwent a germline multigene panel for BRCA1\/2 evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 83 patients who underwent PDS, a TTC \u2265 60 days was associated with a shorter PFS (hazard ratio (HR) 2.02, 95% confidence interval (CI) 1.04\u20133.93,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.038), although this association lost statistical significance when adjusting for residual disease (HR 1.52, 95% CI 0.75\u20133.06,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.244, for TTC and HR 2.73, 95% CI 1.50\u20134.96,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001, for residual disease). Among 52 IDS patients, we found no evidence of an association between TTC and clinical outcomes. Ascites, type of chemotherapy, or germline BRCA1\/2 mutational status did not influence TTC and were not associated with clinical outcomes in PDS or IDS patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In conclusion, longer TTC seems to negatively affect prognosis in patients undergoing PDS, especially those with residual disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2023.1221096","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T09:19:59Z","timestamp":1692263999000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Alberto","family":"Farolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Petracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Gurioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tedaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Stefanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Luca","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Cursano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zampiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cangini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Schepisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.004","article-title":"Electronic address: clinicalguidelines@esmo.org. Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines","volume":"32","author":"Colombo","year":"2021","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"ijgc","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"2019","author":"Colombo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.065","article-title":"Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study","volume":"23","author":"Gadducci","year":"2005","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.07.023","article-title":"Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials","volume":"49","author":"Mahner","year":"2013","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2013.07.086","article-title":"The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study","volume":"131","author":"Hofstetter","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.04.004","article-title":"Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer","volume":"133","author":"Lydiksen","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.003","article-title":"Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer","volume":"51","author":"Farolfi","year":"2015","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.749","article-title":"Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis","volume":"305","author":"Biagi","year":"2011","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.03.043","article-title":"Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery","volume":"137","author":"Benedetti Panici","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15789","DOI":"10.3390\/ijms232415789","article-title":"Clinical impact of next-generation sequencing multi-gene panel highlighting the landscape of germline alterations in ovarian cancer patients","author":"Gurioli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum Mutat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9461","DOI":"10.1038\/s41598-017-10197-1","article-title":"Relationship between initiation time of adjuvant chemotherapy and survival in ovarian cancer patients: a dose-response meta-analysis of cohort studies","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.23736\/S0026-4806.19.06078-6","article-title":"Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis","volume":"110","author":"Chiofalo","year":"2019","journal-title":"Minerva Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051058","article-title":"Does time-to-chemotherapy after primary complete macroscopic cytoreductive surgery influence prognosis for patients with epithelial ovarian cancer? A study of the FRANCOGYN group","volume":"10","author":"Rocher","year":"2021","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.09.015","article-title":"The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology\/Gynecologic Oncology Group trials","volume":"143","author":"Chan","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv500","article-title":"Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology\/Gynecologic Oncology Group study","volume":"27","author":"Tewari","year":"2016","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.07.025","article-title":"Time-interval to adjuvant chemotherapy and postoperative management after upper abdominal surgical procedures in advanced ovarian cancer","volume":"47","author":"Joneborg","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2022.33.e76","article-title":"The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study","volume":"33","author":"Lee","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009786.pub3","article-title":"Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer","volume":"3","author":"van de Vrie","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/08941939.2022.2045397","article-title":"Laparoscopic interval debulking surgery for ovarian cancer: fagotti versus PCI score for patients' Selection","volume":"35","author":"Fotiou","year":"2022","journal-title":"J Invest Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.08.025","article-title":"Diagnostic flow-chart to identify bowel involvement in patients with stage IIIC-IV ovarian cancer: Can laparoscopy improve the accuracy of CT scan","volume":"155","author":"Tozzi","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.01.013","article-title":"A prospective study on the diagnostic pathway of patients with stage IIIC-IV ovarian cancer: Exploratory laparoscopy (EXL) + CT scan VS. CT scan","volume":"161","author":"Tozzi","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.11.023","article-title":"Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer","volume":"148","author":"Lee","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B30","article-title":"Final overall survival and long-term safety in the ENGOT-OV16\/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer","author":"Matulonis","year":"2023","journal-title":"Presented at Soc Gynecological Oncol 2023 Virtual Annu Meeting Women\u2019s Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"NEJM"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"NEJM"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"NEJM"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.17517","article-title":"Trends in primary treatment and median survival among women with advanced-stage epithelial ovarian cancer in the US from 2004 to 2016","volume":"3","author":"Knisely","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1221096\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T02:48:46Z","timestamp":1694573326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1221096\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":34,"alternative-id":["10.3389\/fonc.2023.1221096"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1221096","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"article-number":"1221096"}}